Please assess the completion status of the following clinical trial:

Trial Title: Dose Finding Study for a Botulinum Toxin Type A Injection to Treat Habitual Snoring

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female or male subjects aged 18-70~* Subjects suffering from snoring for at least 3 months prior to the study start and seeking for help to treat snoring~* Subjects with a peak Snoring Index \[SI\] ≥ 15/ hour of sleep \[h\] at baseline visit~* Subjects with a bed partner for at least three months prior to study start.~* Subjects who understand the nature of the study and provide written Informed Consent at screening visit.~* Subjects who understand the study procedures as well as possess the ability and willingness to abide by all procedures during the course of the study~Exclusion Criteria:~* Obese subjects (Body Mass Index ≥ 30)~* Subjects with severe obstructive sleep apnea syndrome~* Subjects with Apnea-Hypopnea Index ≥ 10 /hour of sleep and/ or Respiratory Disturbance Index ≥ 25 / hour of sleep at the baseline visit~* Subjects who have undergone any Botulinum neurotoxin treatment in the history~* Subjects with generalized disorders of muscle activity (e.g. myasthenia gravis, Lambert-Eaton syndrome)~* Acute infections of the pharynx

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- IncobotulinumtoxinA (Xeomin) 2.5 Units [U], 5U and 7.4U (Type: EXPERIMENTAL): IncobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection.
- Placebo Comparator (Type: PLACEBO_COMPARATOR): Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).